Advancing the next generation of abuse-deterrent therapeutics for patients with chronic pain
Collegium (NASDAQ: COLL) is a specialty pharmaceuticals company focused on developing and commercializing abuse-deterrent products to address the growing problems associated with non-medical use, abuse, and misuse of prescription products. The company's products are based on its proprietary DETERx® technology platform, which protects against misuse such as breaking, crushing, or dissolving. The company's lead product, Xtampza ER, is an abuse-deterrent, extended-release formulation of oxycodone that has received Fast Track designation from the FDA. Collegium completed its IPO in 2015.